S.R. Blacksburg

A Retrospective Review of CyberKnife Stereotactic Body Radiotherapy for Adrenal Tumors (Primary and Metastatic): Winthrop University Hospital Experience

The adrenal gland is a common site of cancer metastasis. Surgery remains a mainstay of treatment for solitary adrenal metastasis. For patients who cannot undergo surgery, radiation is an alternative option. Stereotactic body radiotherapy (SBRT) is an ablative treatment option allowing larger doses to be delivered over a shorter period of time. In this study, we report on our experience with the use of SBRT to treat adrenal metastases using CyberKnife technology. We retrospectively reviewed the Winthrop University radiation oncology data base to identify 14 patients for whom SBRT was administered to treat malignant adrenal disease. Of the factors examined, the biological equivalent dose (BED) of radiation delivered was found to be the most important predictor of local adrenal tumor control. We conclude that CyberKnife-based SBRT is a safe, non-invasive modality that has broadened the therapeutic options for the treatment of isolated adrenal metastases.

Previous Cryotherapy and Older Age Predict for Faster Biochemical Response After Definitive SBRT for Prostate Cancer.

Conclusions: Table 1: Univariate Analysis, PSA Decline •Stereotactic Body Radiation Therapy (SBRT) remains an emerging treatment option for men with prostate adenocarcinoma with low or intermediate risk disease. •Despite a growing volume of investigation, there is a paucity of data that characterizes predictors of post-treatment PSA kinetics in the initial six-month window. •Cryosurgery is an evolving minimally invasive therapy for the treatment of focal prostate cancer. •The effect of previous cryosurgery on PSA kinetics following salvage SBRT has not been previously explored. •This study reports the effect of age and previous cryosurgery on initial PSA kinetics for patients that have undergone definitive SBRT for low or intermediate risk prostate cancer.

Young age to predict for transient elevation in PSA after definitive stereotactic body radiation therapy for prostate cancer.

118 Background: Stereotactic Body Radiation Therapy (SBRT) is a standard therapeutic option for men with prostate adenocarcinoma. There is a small body of literature characterizing a PSA bump after treatment with SBRT. Despite this, there is a paucity of data addressing rates of transient PSA increase immediately after SBRT treatment and what factors portend for this rare occurrence. This study reports outcomes on initial PSA after SBRT therapy for men who have received definitive SBRT for prostate cancer. Methods: Between May 2006 and February 2014, 921 patients with prostate cancer were treated with SBRT delivered via Cyberknife therapy. The mean age was 67 years old. 68.5% of patients were Caucasian, 17.4% African American, and 14.1% were another ethnicity. Patients were divided into prognostic risk groups with 44.7%, 43.5%, and 11.1% of patients falling in the low, intermediate, and high risk stratifications. Gleason scores were < 6 in 44.4%, 7 in 41.3%, and 8-10 in 14.2%. 37 patients also received su...